Safety of "hot" and "cold" site admissions within a high-volume urology department in the United Kingdom at the peak of the COVID-19 pandemic.
Journal
BJUI compass
ISSN: 2688-4526
Titre abrégé: BJUI Compass
Pays: United States
ID NLM: 101764975
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
15
08
2020
revised:
25
09
2020
accepted:
10
10
2020
entrez:
6
4
2021
pubmed:
7
4
2021
medline:
7
4
2021
Statut:
ppublish
Résumé
To determine the safety of urological admissions and procedures during the height of the COVID-19 pandemic using "hot" and "cold" sites. The secondary objective is to determine risk factors of contracting COVID-19 within our cohort. A retrospective cohort study of all consecutive patients admitted from March 1 to May 31, 2020 at a high-volume tertiary urology department in London, United Kingdom. Elective surgery was carried out at a "cold" site requiring a negative COVID-19 swab 72-hours prior to admission and patients were required to self-isolate for 14-days preoperatively, while all acute admissions were admitted to the "hot" site.Complications related to COVID-19 were presented as percentages. Risk factors for developing COVID-19 infection were determined using multivariate logistic regression analysis. A total of 611 patients, 451 (73.8%) male and 160 (26.2%) female, with a median age of 57 (interquartile range 44-70) were admitted under the urology team; 101 (16.5%) on the "cold" site and 510 (83.5%) on the "hot" site. Procedures were performed in 495 patients of which eight (1.6%) contracted COVID-19 postoperatively with one (0.2%) postoperative mortality due to COVID-19. Overall, COVID-19 was detected in 20 (3.3%) patients with two (0.3%) deaths. Length of stay was associated with contracting COVID-19 in our cohort (OR 1.25, 95% CI 1.13-1.39). Continuation of urological procedures using "hot" and "cold" sites throughout the COVID-19 pandemic was safe practice, although the risk of COVID-19 remained and is underlined by a postoperative mortality.
Identifiants
pubmed: 33821256
doi: 10.1002/bco2.56
pii: BCO256
pmc: PMC8013895
doi:
Types de publication
Journal Article
Langues
eng
Pagination
97-104Informations de copyright
© 2021 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.
Déclaration de conflit d'intérêts
The Authors do not declare any conflict of interest. Funding has been provided the department of Life Sciences and Medicine, King’s College London.
Références
N Engl J Med. 2020 Jun 25;382(26):2534-2543
pubmed: 32459916
BJUI Compass. 2021 Mar;2(2):97-104
pubmed: 33821256
Ann R Coll Surg Engl. 2020 Jun 27;:1-6
pubmed: 32594751
Br J Surg. 2020 Aug;107(9):1097-1103
pubmed: 32293715
Lancet. 2020 Jul 4;396(10243):27-38
pubmed: 32479829
EClinicalMedicine. 2020 Jun 03;23:100404
pubmed: 32632416
EClinicalMedicine. 2020 Apr 05;21:100331
pubmed: 32292899
Br J Surg. 2020 Oct;107(11):1440-1449
pubmed: 32395848
Int J Surg. 2020 Dec;84:57-65
pubmed: 33122153
Cleve Clin J Med. 2020 May 14;:
pubmed: 32409430
Lancet. 2020 Mar 14;395(10227):e46
pubmed: 32113507
Eur Urol. 2020 Aug;78(2):265-275
pubmed: 32507625
World J Surg. 2020 Jun;44(6):1695-1698
pubmed: 32246185